Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1121970

	registered interest
	date	18/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 April 2019 to Question 242692 on Cancer: Drugs, what steps the Government is taking to give timely NICE and NHS approval to enable access to maintenance medication for people with cancer.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	245610
	answer	answer is ministerial correction date of answer 25/04/2019 answer text <p>Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether drugs and other treatments represent an effective use of NHS resources. NHS England is legally required to fund cancer drugs recommended in NICE technology appraisal guidance.</p><p>The Government wants patients with cancer to be able to benefit from rapid access to effective new drugs, including for maintenance treatment. Under arrangements introduced in 2016, NICE now develops technology appraisal guidance for the NHS on all new cancer drugs. Wherever possible, NICE aims to issue draft guidance on new cancer drugs before licensing and to publish final guidance within 90 days of licensing.</p><p>Funding is available through the Cancer Drugs Fund from the point at which NICE draft recommendations are published, or if the drug is not currently licensed, from the point of licensing. This ensures patients are able to benefit from effective new cancer drugs as quickly as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 25/04/2019 14:05:35 answering member 4455 label Biography information for Seema Kennedy
	tabling member	394 label Biography information for Mr Clive Betts

1124146

	registered interest
	date	01/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 April 2019 to Question 245610, how many forms of cancer have no maintenance drug available at any stage in the treatment plan.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	249828
	answer	answer is ministerial correction date of answer 08/05/2019 answer text <p>The information requested is not available.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 08/05/2019 13:54:02 answering member 4455 label Biography information for Seema Kennedy
	tabling member	394 label Biography information for Mr Clive Betts

1172080

	registered interest
	date	20/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the proposed Innovative Medicines Fund does not adversely affect funding available for cancer drugs.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	5324
	answer	answer is ministerial correction date of answer 23/01/2020 answer text <p>The Cancer Drugs Fund will be extended to create a new Innovative Medicines Fund so that doctors can use the most advanced, life-saving treatments for conditions such as autoimmune disease or cancer, or for children with other rare diseases.</p><p>Detailed proposals for the new Innovative Medicines Fund are in development and will be consulted on in due course. The will extend the successes of the reformed Cancer Drugs Fund into other areas.</p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 5325 question first answered 23/01/2020 12:16:26 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1172081

	registered interest
	date	20/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to consult on his proposed reforms to the Cancer Drugs Fund.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	5325
	answer	answer is ministerial correction date of answer 23/01/2020 answer text <p>The Cancer Drugs Fund will be extended to create a new Innovative Medicines Fund so that doctors can use the most advanced, life-saving treatments for conditions such as autoimmune disease or cancer, or for children with other rare diseases.</p><p>Detailed proposals for the new Innovative Medicines Fund are in development and will be consulted on in due course. The will extend the successes of the reformed Cancer Drugs Fund into other areas.</p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 5324 question first answered 23/01/2020 12:16:26 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1175547

	registered interest
	date	03/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, which patient organisations are members of the (a) modifiers considered in decision-making, (b) exploring uncertainty, (c) types of evidence, (d) health-related quality of life, (e) technology specific issues, (f) discounting, (g) cost-minimisation methods (h) costs used in HTA, (i) equality considerations in guideline development, (j) general approach to decision-making and (k) position of technologies in care pathway, NICE methods review task and finish groups.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	11443
	answer	answer is ministerial correction date of answer 06/02/2020 answer text <p>The following patient groups are currently involved across the programme of task and finish groups. The National Institute for Health and Care Excellence (NICE) has advised that it continues to seek further members for the task and finish groups, and a full list of members is still to be finalised.</p><p>- Alzheimer's Research UK;</p><p>- Breast Cancer Now;</p><p>- Cancer52;</p><p>- Cystic Fibrosis Trust ;</p><p>- Diabetes UK;</p><p>- Genetic Alliance UK;</p><p>- Leukaemia CARE;</p><p>- Multiple Sclerosis Society;</p><p>- Muscular Dystrophy UK;</p><p>- Myeloma UK;</p><p>- Neuroendocrine Cancer UK;</p><p>- Prostate cancer UK; and</p><p>- Sarcoma UK.</p><p> </p><p>In recruiting patient organisations to the NICE methods review task and finish groups, patients on the methods working group were asked to nominate representatives with a range of experience. Additional representatives were nominated by NICE where particular expertise or input was required. The organisations involved in the task and finish groups cover a broad spectrum of disease areas including cancer, non-cancer and rare diseases.<strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 11444 question first answered 06/02/2020 17:20:14 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1175548

	registered interest
	date	03/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how patient organisations were recruited to the 11 NICE methods review task and finish groups.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	11444
	answer	answer is ministerial correction date of answer 06/02/2020 answer text <p>The following patient groups are currently involved across the programme of task and finish groups. The National Institute for Health and Care Excellence (NICE) has advised that it continues to seek further members for the task and finish groups, and a full list of members is still to be finalised.</p><p>- Alzheimer's Research UK;</p><p>- Breast Cancer Now;</p><p>- Cancer52;</p><p>- Cystic Fibrosis Trust ;</p><p>- Diabetes UK;</p><p>- Genetic Alliance UK;</p><p>- Leukaemia CARE;</p><p>- Multiple Sclerosis Society;</p><p>- Muscular Dystrophy UK;</p><p>- Myeloma UK;</p><p>- Neuroendocrine Cancer UK;</p><p>- Prostate cancer UK; and</p><p>- Sarcoma UK.</p><p> </p><p>In recruiting patient organisations to the NICE methods review task and finish groups, patients on the methods working group were asked to nominate representatives with a range of experience. Additional representatives were nominated by NICE where particular expertise or input was required. The organisations involved in the task and finish groups cover a broad spectrum of disease areas including cancer, non-cancer and rare diseases.<strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 11443 question first answered 06/02/2020 17:20:14 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1175549

	registered interest
	date	03/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps the NICE methods review task and finish groups will take to consult with the wider health charity sector.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	11445
	answer	answer is ministerial correction date of answer 06/02/2020 answer text <p>The National Institute for Heath and Care Excellence (NICE) has advised that a six week public consultation on the proposals for changing its methods and processes will take place this summer. We understand that further work on the timetable is in progress and will be communicated in due course.</p><p>The wider health charity sector will have an opportunity to review the proposals for change from the task and finish groups during this consultation.</p><p>NICE also held a webinar with stakeholders in November 2019 to share how and why health technology evaluation is changing and what it means for patients. The webinar is available on the NICE website at the following link:</p><p><a href="https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation" target="_blank">https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation</a></p><p>NICE staff have also participated in a number of events to engage with the patient community, including the charity sector and about the methods review.</p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 11446 question first answered 06/02/2020 17:21:30 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1175550

	registered interest
	date	03/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the timetable is for the publication of the full consultation on the proposed reforms to NICE methods and processes.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	11446
	answer	answer is ministerial correction date of answer 06/02/2020 answer text <p>The National Institute for Heath and Care Excellence (NICE) has advised that a six week public consultation on the proposals for changing its methods and processes will take place this summer. We understand that further work on the timetable is in progress and will be communicated in due course.</p><p>The wider health charity sector will have an opportunity to review the proposals for change from the task and finish groups during this consultation.</p><p>NICE also held a webinar with stakeholders in November 2019 to share how and why health technology evaluation is changing and what it means for patients. The webinar is available on the NICE website at the following link:</p><p><a href="https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation" target="_blank">https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation</a></p><p>NICE staff have also participated in a number of events to engage with the patient community, including the charity sector and about the methods review.</p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 11445 question first answered 06/02/2020 17:21:30 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1242957

	registered interest
	date	13/10/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Coronavirus
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to develop advice for people who were previously shielding tailored to the risk associated with their particular disease, including different types of blood cancer, in the event that further restrictions are introduced as a result of the covid-19 outbreak.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	102671
	answer	answer is ministerial correction date of answer 23/10/2020 answer text <p>Shielding was paused on 1 August 2020 in England; however, it is important that clinically extremely vulnerable people continue to take extra care, particularly as infection rates rise again. On 13 October, the Government published new guidance to the clinically extremely vulnerable that advises additional things they are advised to do to keep themselves safe at each local COVID alert level.</p><p>In the future, the Government will only reintroduce shielding advice in the very worst affected areas and for a limited period of time. This decision will be based on advice from the Chief Medical Officer, informed by local public health experts.</p><p>The National Health Service is continuing to maintain the shielded patient list, allowing us to maintain targeted advice and support to those who are most vulnerable and to change advice and support if necessary. General practitioners and hospital clinicians remain able to add people to the list, based on clinical judgement and an assessment of an individual’s needs.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 23/10/2020 13:37:18 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1243368

	registered interest
	date	14/10/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Multiple Myeloma: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when assessment he has made of the timescale for the approval of lenalidomide as a maintenance drug for post stem cell transplant treatment of Myeloma.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	103426
	answer	answer is ministerial correction date of answer 22/10/2020 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing guidance on lenalidomide for the maintenance treatment of multiple myeloma after autologous stem cell transplantation.</p><p>NICE expects to publish final guidance on lenalidomide in January 2021.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 22/10/2020 09:38:06 answering member 4380 label Biography information for Jo Churchill previous answer version 55271 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts